Four-Drug Combination Effective Long-Term for HIV Suppression Four-Drug Combination Effective Long-Term for HIV Suppression
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for long-term viral suppression in previously untreated patients with HIV-1 infection, according to 96-week results from the AMBER trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Facebook Asked to Remove'Factually Inaccurate' Ads About PrEP
THURSDAY, Dec. 12, 2019 -- Facebook should remove " factually inaccurate " ads that " suggest negative health effects " of the HIV-prevention medication Truvada, more than 50 LGBTQ, HIV, and public health groups say in an open letter to the company.
The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2019 Category: Pharmaceuticals Source Type: news
Activists and LGBTQ Groups Say These Facebook Ads Spread Dangerous Misinformation About HIV Drugs
Advocacy groups are urging Facebook to remove advertisements that they say unfairly infer that the HIV/AIDS prevention Truvada PrEP (pre-exposure prophylaxis) is dangerous, an allegation they say could endanger the people who are most at risk of contracting the disease.
More than 50 HIV/AIDs, LGBTQ and public health advocacy groups released a letter on Monday asking Facebook and Instagram to remove the ads from their platforms.
The ads referred specifically to “Truvada PrEP” (the brand name for one of the medications, dtenofovir disoproxil fumarate, used as PrEP) and in some cases more generically to “PrE...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized health LGBTQ onetime Source Type: news
200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs
A new government program will provide donated drugs through major drugstore chains. (Source: NYT Health)
Source: NYT Health - December 3, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome PrEP (Pre-exposure prophylaxis for H.I.V.) Truvada (Drug) Gilead Sciences Inc Health and Human Services Department Azar, Alex M II Drugs (Pharmaceuticals) Tests (Medical) Health Insurance and Managed Car Source Type: news
200,000 People Without Insurance May Apply for Free H.I.V.-Prevention Drugs
A new government program will provide donated drugs through major drugstore chains. (Source: NYT Health)
Source: NYT Health - December 3, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. Tags: Acquired Immune Deficiency Syndrome PrEP (Pre-exposure prophylaxis for H.I.V.) Truvada (Drug) Gilead Sciences Inc Health and Human Services Department Azar, Alex M II Drugs (Pharmaceuticals) Tests (Medical) Health Insurance and Managed Car Source Type: news
Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says
In an unexpected lawsuit, federal officials claim that Gilead Sciences willfully disregarded government patents on medicines necessary to end the AIDS epidemic. (Source: NYT Health)
Source: NYT Health - November 8, 2019 Category: Consumer Health News Authors: Donald G. McNeil Jr. and Apoorva Mandavilli Tags: Acquired Immune Deficiency Syndrome Truvada (Drug) Inventions and Patents Drugs (Pharmaceuticals) Royalties Health and Human Services Department National Institutes of Health Azar, Alex M II Cummings, Elijah E Stabenow, Debbie Source Type: news
Trump Administration Sues Gilead, Maker of H.I.V.-Prevention Drugs
The lawsuit accused the pharmaceutical company of profiting billions of dollars off taxpayer research without paying royalties. (Source: NYT Health)
Source: NYT Health - November 7, 2019 Category: Consumer Health News Authors: Daniel Victor Tags: Gilead Sciences Inc Truvada (Drug) Health and Human Services Department Inventions and Patents Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Source Type: news
California Makes H.I.V.-Prevention Drugs Available Without a Prescription
The state is the first in the nation to allow pharmacists to dispense PrEP and PEP, drugs that can prevent new H.I.V. infections. (Source: NYT Health)
Source: NYT Health - October 9, 2019 Category: Consumer Health News Authors: Karen Zraick and Sandra E. Garcia Tags: Drugs (Pharmaceuticals) Truvada (Drug) Acquired Immune Deficiency Syndrome Drug Resistance (Microbial) Drugstores Equality California Newsom, Gavin Source Type: news
F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Everyone
Citing a lack of evidence, the agency will require Gilead to conduct additional trials in individuals ‘who have receptive vaginal sex.’ (Source: NYT Health)
Source: NYT Health - October 8, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news
F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Cisgender Women
Citing a lack of evidence, the agency will require Gilead to conduct additional trials. (Source: NYT Health)
Source: NYT Health - October 8, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news
F.D.A. Approves New H.I.V.-Prevention Drug, but Not for Women
Citing a lack of evidence, the agency will require Gilead to conduct further trials in women. (Source: NYT Health)
Source: NYT Health - October 4, 2019 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: Truvada (Drug) Women and Girls Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Inventions and Patents Transgender and Transsexuals Food and Drug Administration Gilead Sciences Inc your-feed-health Descovy Source Type: news
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) indication for Descovy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 3, 2019 Category: Drugs & Pharmacology Source Type: news
FDA OKs Descovy, Second Drug for HIV PrEP FDA OKs Descovy, Second Drug for HIV PrEP
The combo of emtricitabine and tenofovir alafenamide is indicated to reduce the risk for HIV-1 infection from sex (excluding receptive vaginal sex) in at-risk adults and teens weighing at least 35 kg.FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 3, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news
FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Source: World Pharma News)
Source: World Pharma News - October 3, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Gilead to challenge US patents on HIV drug Truvada
Move comes amid increasing scrutiny of drugmaker over pricing practices (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 21, 2019 Category: Pharmaceuticals Source Type: news
